PURPOSE:Hepatocyte growth factor (HGF) is a hypoxia-induced secreted protein that binds to cMet and regulates interleukin (IL)-8 expression. We evaluated the role of circulating HGF and IL-8 as prognostic and predictive factors for efficacy of tirapazamine (TPZ), a hypoxic cell cytotoxin. EXPERIMENTAL DESIGN:Patients with stages III to IV head and neck cancer were randomized to receive radiotherapy with cisplatin (CIS) or CIS plus TPZ (TPZ/CIS). Eligibility for the substudy included plasma sample availability for HGF and IL-8 assay by ELISA and no major radiation deviations (N = 498). Analyses included adjustment for major prognostic factors. p16(INK4A) staining (human papillomavirus surrogate) was carried out on available tumors. Thirty-nine patients had hypoxia imaging with (18)F-fluoroazomycin arabinoside ((18)FAZA)-positron emission tomography. RESULTS:Elevated IL-8 level was associated with worse overall survival (OS) irrespective of treatment. There was an interaction between HGF and treatment arm (P = 0.053); elevated HGF was associated with worse OS in the control but not in the TPZ/CIS arm. Similar trends were observed in analyses restricted to p16(INK4A)-negative patients. Four subgroups defined by high and low HGF/IL-8 levels were examined for TPZ effect; the test for interaction with arm was P = 0.099. TPZ/CIS seemed to be beneficial for patients with high HGF andIL-8 but adverse for low HGF and high IL-8. Only HGF correlated with (18)FAZA tumor standard uptake value. CONCLUSIONS:IL-8 is an independent prognostic factor irrespective of treatment. There is an interaction between HGF and treatment arm. Certain subgroups based on IL-8/HGF levels seemed to do better with TPZ/CIS while others did worse, highlighting the complexity of hypoxia targeting in unselected patients.
RCT Entities:
PURPOSE:Hepatocyte growth factor (HGF) is a hypoxia-induced secreted protein that binds to cMet and regulates interleukin (IL)-8 expression. We evaluated the role of circulating HGF and IL-8 as prognostic and predictive factors for efficacy of tirapazamine (TPZ), a hypoxic cell cytotoxin. EXPERIMENTAL DESIGN:Patients with stages III to IV head and neck cancer were randomized to receive radiotherapy with cisplatin (CIS) or CIS plus TPZ (TPZ/CIS). Eligibility for the substudy included plasma sample availability for HGF and IL-8 assay by ELISA and no major radiation deviations (N = 498). Analyses included adjustment for major prognostic factors. p16(INK4A) staining (human papillomavirus surrogate) was carried out on available tumors. Thirty-nine patients had hypoxia imaging with (18)F-fluoroazomycin arabinoside ((18)FAZA)-positron emission tomography. RESULTS: Elevated IL-8 level was associated with worse overall survival (OS) irrespective of treatment. There was an interaction between HGF and treatment arm (P = 0.053); elevated HGF was associated with worse OS in the control but not in the TPZ/CIS arm. Similar trends were observed in analyses restricted to p16(INK4A)-negative patients. Four subgroups defined by high and low HGF/IL-8 levels were examined for TPZ effect; the test for interaction with arm was P = 0.099. TPZ/CIS seemed to be beneficial for patients with high HGF and IL-8 but adverse for low HGF and high IL-8. Only HGF correlated with (18)FAZAtumor standard uptake value. CONCLUSIONS:IL-8 is an independent prognostic factor irrespective of treatment. There is an interaction between HGF and treatment arm. Certain subgroups based on IL-8/HGF levels seemed to do better with TPZ/CIS while others did worse, highlighting the complexity of hypoxia targeting in unselected patients.
Authors: Carole Fakhry; William H Westra; Sigui Li; Anthony Cmelak; John A Ridge; Harlan Pinto; Arlene Forastiere; Maura L Gillison Journal: J Natl Cancer Inst Date: 2008-02-12 Impact factor: 13.506
Authors: Tanguy Y Seiwert; Ramasamy Jagadeeswaran; Leonardo Faoro; Varalakshmi Janamanchi; Vidya Nallasura; Mohamed El Dinali; Soheil Yala; Rajani Kanteti; Ezra E W Cohen; Mark W Lingen; Leslie Martin; Soundararajan Krishnaswamy; Andres Klein-Szanto; James G Christensen; Everett E Vokes; Ravi Salgia Journal: Cancer Res Date: 2009-03-24 Impact factor: 12.701
Authors: Lynn M Knowles; Laura P Stabile; Ann Marie Egloff; Mary E Rothstein; Sufi M Thomas; Christopher T Gubish; Edwina C Lerner; Raja R Seethala; Shinsuke Suzuki; Kelly M Quesnelle; Sarah Morgan; Robert L Ferris; Jennifer R Grandis; Jill M Siegfried Journal: Clin Cancer Res Date: 2009-05-26 Impact factor: 12.531
Authors: Sheila E Taube; Gary M Clark; Janet E Dancey; Lisa M McShane; Caroline C Sigman; Steven I Gutman Journal: J Natl Cancer Inst Date: 2009-10-23 Impact factor: 13.506
Authors: Hsin-Yu Fang; Russell Hughes; Craig Murdoch; Seth B Coffelt; Subhra K Biswas; Adrian L Harris; Randall S Johnson; Hongxia Z Imityaz; M Celeste Simon; Erik Fredlund; Florian R Greten; Jordi Rius; Claire E Lewis Journal: Blood Date: 2009-05-19 Impact factor: 22.113
Authors: Praveen K Gulaka; Federico Rojas-Quijano; Zoltan Kovacs; Ralph P Mason; A Dean Sherry; Vikram D Kodibagkar Journal: J Biol Inorg Chem Date: 2013-11-27 Impact factor: 3.358
Authors: Paul L Swiecicki; Lili Zhao; Emily Belile; Assuntina G Sacco; Douglas B Chepeha; Irina Dobrosotskaya; Matthew Spector; Andrew Shuman; Kelly Malloy; Jeffrey Moyer; Erin McKean; Scott McLean; Gregory T Wolf; Avraham Eisbruch; Mark Prince; Carol Bradford; Thomas Carey; Francis P Worden Journal: Invest New Drugs Date: 2015-10-10 Impact factor: 3.850
Authors: Clemens Grassberger; Susannah G Ellsworth; Moses Q Wilks; Florence K Keane; Jay S Loeffler Journal: Nat Rev Clin Oncol Date: 2019-06-26 Impact factor: 66.675
Authors: Vasiliki A Papadimitrakopoulou; Steven J Frank; Ezra W Cohen; Fred R Hirsch; Jeffrey N Myers; John V Heymach; Heather Lin; Hai T Tran; Changhu R Chen; Antonio Jimeno; Lucien Nedzi; Joseph R Vasselli; Elizabeth S Lowe; David Raben Journal: Head Neck Date: 2015-06-16 Impact factor: 3.147
Authors: Jennifer H E Baker; Alastair H Kyle; Kirsten L Bartels; Stephen P Methot; Erin J Flanagan; Andrew Balbirnie; Jordan D Cran; Andrew I Minchinton Journal: PLoS One Date: 2013-10-28 Impact factor: 3.240